Future of flu vaccines. Expediting clinical trials in a pandemic.

Geahča maid

• Future of flu vaccines. Expediting clinical trials in a pandemic.
  Dahkki: Pollard, A, et al.
  Almmustuhtton: (2009)
• Relationships between reactogenicity and age, dose number and immunogenicity in 937 children receiving two doses of ASO3(B)-adjuvanted split virion or whole virus H1N1 influenza A 2009 pandemic vaccines
  Dahkki: Walker, W, et al.
  Almmustuhtton: (2011)
• Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
  Dahkki: Waddington, C, et al.
  Almmustuhtton: (2010)
• Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study
  Dahkki: Waddington, C, et al.
  Almmustuhtton: (2010)
• Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
  Dahkki: Waddington, C, et al.
  Almmustuhtton: (2010)